Study of Safety and Efficacy of RGT-61159 in Adults with Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC
Adenoid Cystic Carcinoma|Colorectal Cancer
DRUG: RGT-61159
Number and type of dose-limiting toxicities (DLTs) in first cycle of administration, 21 days|Number and type of adverse events, Through study completion, estimated as 30 days after last dose of study drug|Recommended Phase 2 Dose (RP2D), Assessed at the end of Cycle 1 for each subject (each cycle 21 days)
This first-in-human, Phase 1, multi-center, open-label, non-randomized study, is designed to evaluate safety, tolerability, and anti-tumor activity of once-daily RGT-61159 in patients with advanced R/R ACC or R/R CRC for whom standard therapy with proven clinical benefit does not exist, is no longer effective, or is not appropriate. RGT-61159 is an oral, small molecule MYB inhibitor.